A 5-year Superion™ IDS Clinical Outcomes Post-Approval Evaluation (SCOPE)
← catalyst calendarNCT04192591 · readout ≤ 4,211 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
166actual
Sites
23
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-01-30 | actual | When the study began enrolling |
| Primary completion | Feb 2038 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2041 | estimated | The whole study's end, after follow-up |
| First posted | 2019-12-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lumbar Spinal Stenosis
Intervention
- Device: Superion™ IDS device
Primary outcome
what the primary-completion date above is the date OFRate of success at the 24-month follow-up visit
measured 24-Months
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed